Please login to the form below
psoriatic arthritis
This page shows the latest psoriatic arthritis news and features for those working in and with pharma, biotech and healthcare.
US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case
Erelzi references Amgen’s blockbuster arthritis drug Enbrel (etanercept) – Sandoz had been hoping to launch the biosimilar as a ‘more affordable’ treatment option for US patients. ... Enbrel, which yielded approximately $5bn in sales in 2020, was
Latest news
-
FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
Xeljanz is approved in the US for use in adults with rheumatoid arthritis (RA) who have not responded well to methotrexate treatment. ... It is also approved to treat patients with psoriatic arthritis who have not responded well to prior methotrexate
-
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
It also has registration trials for Skyrizi ongoing in Crohn's disease and ulcerative colitis due to generate results next year, as well as studies in psoriatic arthritis and atopic dermatitis ... Novartis’ drug is currently approved for adults with
-
J&J splashes $750m on anti-inflammatory drug bermekimab
J&J is already a leader in the immunology market, and recently filed its next-generation IL-23 inhibitor Tremfya in psoriatic arthritis (PsA) with the European Medicines Agency.
-
Amgen raises forecasts after closing $13.4bn Otezla deal
Otezla grew 26% to reach $1.6bn in sales across its psoriasis, psoriatic arthritis and Behçet's disease indications last year, and has continued its expansion this year with a tally
-
Novartis’ Cosentyx misses the mark in Humira head-to-head
Narrowly missed statistical significance for superiority. Novartis’ Cosentyx (secukinumab) failed to show significant superiority over AbbVie’s Humira (adalimumab) in a head-to-head trial in psoriatic arthritis (PsA). ... We will assess the EXCEED
FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
J&J splashes $750m on anti-inflammatory drug bermekimab
Amgen raises forecasts after closing $13.4bn Otezla deal
Novartis’ Cosentyx misses the mark in Humira head-to-head
More from news
Approximately 15 fully matching, plus 122 partially matching documents found.
Latest Intelligence
-
Helping patients to help themselves – how pharma can get more from patient support programmes
For example, when developing a patient support programme for patients with Ankylosing Spondylitis and Psoriatic Arthritis, earthware identified that, for newly diagnosed patients, the impact of receiving the diagnosis on their
-
Innovation in a digital context is not about technology – it’s about people
Putting it into practice. This process is well illustrated through our development of Psoriasis360.co.uk, a website to support people with psoriatic disease. ... We have also been continuously developing new content based on patients’ needs: an
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... In May last year, approval for Skyrizi was filed in Japan for plaque psoriasis, psoriatic arthritis, pustular
-
Drug launches to watch in 2019
Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other inflammatory conditions. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that indication before the end of the year.
-
The good, the bad and the ugly
Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis. ... Similarly, Novartis has enjoyed 31.7% growth thanks to another psoriasis/psoriatic
Helping patients to help themselves – how pharma can get more from patient support programmes
Innovation in a digital context is not about technology – it’s about people
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Drug launches to watch in 2019
The good, the bad and the ugly
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest from PMHub
-
Changing healthcare, one film at a time
Millefeuille’ [ IMDB] explores the issues of isolation and restriction people with psoriasis and psoriatic arthritis struggle with, and the degree to which they are self-imposed, through the character of Élodie –
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease,
-
Lucid win PMEA Support Agency of the Year 2016
management of psoriatic arthritis.Judges’ comments: “In taking a different approach, this work stands out from the many support programmes already out there.
-
Lucid make the shortlist in all of the four categories they entered for the PMEA programme 2016
um: Changing clinical behaviour on a global scale to improve standards of care in the management of psoriatic arthritis. .
-
Millefeuille
This story of hope charts Élodie’s physical and mental struggles with psoriasis and psoriatic arthritis. ... For more information please visit http://bedrock-health.com/millefeuille/. This story of hope charts Élodie’s physical and mental struggles
More from PMHub
Approximately 1 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- US demand for COVID-19 antibody treatments rising fast
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- EU “still interested” in Valneva COVID vaccine despite UK snub
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- EU “still interested” in Valneva COVID vaccine despite UK snub
- Advancing Drug Discovery with Structured and Intelligent Data
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Ashfield Health announces three new senior hires
- Future of MHRA uncertain amid Brexit-fuelled shake up
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
